DVA - DaVita Inc Stock Analysis

DaVita Inc (DVA) is a publicly traded company listed on the NYSE. It operates in the Medical Care Facilities industry, part of the broader Healthcare sector. The company has a market capitalization of 7.39B, generates annual revenue of 13.32B, and reports net income of 771.91M. As of the latest data, the stock is trading at 104.74 USD.

From a valuation and risk perspective, the stock presents the following profile: The stock appears reasonably valued, potentially indicating balanced risk and return. The PEG ratio is below 1, which may indicate the stock is undervalued relative to its growth potential. The company has very low leverage, which may indicate conservative financial management or underutilization of debt. This stock does not currently pay a dividend. The stock has average market volatility, aligning with general market movement.

Analyst recommendation stands at Sell (2.65), indicating current market sentiment. Institutional ownership is reported at 96.11%, reflecting confidence from large investors. Over the last 12 months, the stock has shown a performance of -35.49%, trading within a 52-week range of 101.00 - 179.60.

DVA - DaVita Inc

104.74
Analyst Consensus
Sell 2.65
DVA – Analyst Rating Summary
Analyst Pie Chart
  • Strong Buy: 0
  • Buy: 1
  • Hold: 10
  • Sell: 5
  • Strong Sell: 1
  • Total Analysts:  17

Last update: 2026-01-20 04:39:29
Index: S&P 500 P/E: 10.78 EPS (ttm): 9.71 Insider Own: 5.42% Shs Outstand: 70.98M Perf Week: -6.02%
Market Cap: 7.39B Forward P/E: 8.19 EPS next Y: 12.80 Insider Trans: -34.77% Shs Float: 66.78M Perf Month: -11.19%
Income(ttm): 771.91M PEG: 0.51 EPS next Q: 3.24 Inst Own: 96.11% Short Float: 12.12% Perf Quarter: -16.38%
Revenue(ttm): 13.32B P/S: 0.56 EPS this Y: 9.08% Inst Trans: -2.05% Short Ratio: 8.92 Perf Half Y: -25.80%
Book/sh: -8.06 P/B: - EPS next Y: 21.19% ROA: 4.40% Short Interest: 8.09M Perf Year: -35.49%
Cash/sh: 11.70 P/C: 8.95 EPS next 5Y: 16.10% ROE: 635.30% 52W Range: 101.00 - 179.60 Perf YTD: -7.81%
Dividend Est.: - P/FCF: 5.71 EPS past 3/5Y: 6.43% 15.27% ROIC: 6.59% 52W High: 179.60 -41.68% Beta: 0.99
Dividend TTM: - Quick Ratio: 1.32 Sales past 3/5Y: 3.32% 2.39% Gross Margin: 26.70% 52W Low: 101.00 3.70% Perf 5Y: -14.93%
Dividend Ex-Date: - Current Ratio: 1.36 EPS Y/Y TTM: 4.37% Oper. Margin: 14.57% RSI (14): 29.32 Volatility: 3.49% 2.51%
Employees: 76000 Debt/Eq: - Sales Y/Y TTM: 5.14% Profit Margin: 5.80% Recom: 2.83 Target Price: 142.29
Option/Short: Yes / Yes LT Debt/Eq: - EPS Q/Q: -18.56% Payout: 0.00% Rel Volume: 0.72 Prev Close: 105.84
Sales Surprise: -0.43% EPS Surprise: -22.08% Sales Q/Q: 4.80% Earnings: Oct 29 AMC Avg Volume: 907.54K Price: 104.74
SMA20: -6.45% SMA50: -10.07% SMA200: -20.68% Undervalued: 35.85%
Volume: 649,782 Change: -1.04%
Graham's revised valuation formula
Discounted cash flow (DCF) model
Margin of safety

About DaVita Inc

DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.

Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.

Copyright © 2024 - 2026 www.stocks-expert.com All Rights Reserved.